Meiji Seika Pharma Opens New Office in Boston Area to Pursue Investment Opportunities in Innovative Drugs and Technologies

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Infectious Diseases

Fitness & Nutrition

COVID-19

Pharmaceutical

Biotechnology

Meiji Seika Pharma Co., Ltd.

More Like This

Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023

Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association

Ribbon Cutting of the Lab (Photo: Business Wire)

Rigaku BioScience Lab Opens in USA

PR Newswire associated0

IRBM Expands Global Reach in Drug Discovery with New Boston Office

Rendering of Merck's new Bioprocessing Production Center in Daejeon, South Korea

Merck Invests More than € 300 Million in New Life Science Production Site in Korea

Kyowa Kirin International and NewBridge Pharmaceuticals Enter Into Agreement to Improve Access to Medicines for Rare Disease Patients Across Middle East and North Africa

SK pharmteco Invests $260 Million to Expand Global Small Molecule and Peptide Production

AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States